A series of launches are expected to continue to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market in the next ten years and challenge the dominance of the TNF inhibitors, especially as biosimilars are increasingly accepted as alternatives to more-expensive branded therapies and as drugs with novel mechanisms of action become available. Interleukin (IL)-17 and IL-23 inhibitors, in particular, are poised to capture substantial sales and, with the diagnosis and drug-treatment rate anticipated to remain relatively steady, could threaten the sales of current market leaders. Targeted synthetic DMARDs, particularly JAK inhibitors, will fulfill the need for orally dosed therapies and increasingly capture early-line patient share.

Questions Answered

  • What impact will current and emerging biosimilars have on the PsA therapy market in the coming years? How will physicians in different markets react to these less-expensive therapies?
  • How will newer agents, especially those offering an alternative to the market-leading TNF inhibitors, change the PsA therapy market? What is the physician perception of these therapies?
  • What emerging therapies do dermatologists and rheumatologists consider the most promising for PsA? What novel mechanisms of action are considered good clinical targets for this disease?
  • What unmet needs remain to be treated in PsA? Will emerging therapies fulfill these needs, and will they be competitive with biosimilars and entrenched branded therapies?

Content Highlights

Geographies: United States, EU5, Japan.

Primary research: 24 country-specific interviews with thought-leading dermatologists and rheumatologists supported by survey data collected for this and other DRG research.

Epidemiology: Number of PsA patients by country, including diagnosed and drug-treated populations.

Forecast: 10-year, annualized, drug-level sales and patient share of key PsA therapies to 2029, segmented by brands / biosimilars.

Emerging therapies: Phase III/PR: 5 drugs; Phase II: 2 drugs.

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Psoriatic Arthritis - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q3 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • November 2020
      • Q3 2020
        • September 2020
    • Key Findings
      • Market Outlook
        • Key Findings
          • Market Share of Drug Classes for PsA: 2019
          • Market Share of Drug Classes for PsA: 2029
          • PsA SWOT Analysis
        • COVID-19: Areas of Potential Forecast Impact
          • Market Drivers and Constraints
            • What Factors Are Driving the Market for PsA?
            • What Factors Are Constraining the Market for PsA?
            • Annual Sales of TNF Inhibitors in PsA: 2019-2029
            • Annual Sales of Select Drugs in PsA: 2019-2029
          • Drug-Class-Specific Trends
            • U.S. Patient Share for TNF Inhibitors in PsA: 2019-2029
            • EU5 Patient Share for TNF Inhibitors in PsA: 2019-2029
            • Japanese Patient Share for TNF Inhibitors in PsA: 2019-2029
            • Major-Market Brand and Biosimilar Sales of Ustekinumab in PsA: 2019-2029
            • Patient Share of Ustekinumab for PsA in the United States, EU5, and Japan: 2019-2029
            • Major-Market Sales of IL-17 Inhibitors for PsA: 2019-2029
            • Major-Market Patient Share of IL-17 Inhibitors in PsA: 2019-2029
            • U.S. Sales and Patient Share of IL-23 Inhibitors in PsA: 2019-2029
            • Sales of Apremilast for PsA in the United States, EU5, and Japan: 2019-2029
            • Major-Market Patient Share and Sales of JAK Inhibitors in PsA: 2019-2029
            • Sales of Abatacept for PsA in the United States and EU5: 2019-2029
        • Forecast
          • Market Forecast Assumptions
          • Market Forecast Dashboard
        • Etiology and Pathophysiology
          • Disease Overview
            • Etiology
              • Risk Factors for PsA
            • Pathophysiology
              • Clinical, Extra-Articular, and Radiographic Features of Various Spondyloarthropathies
              • Pathogenesis
              • Pathological Changes in Early and Late PsA
            • Key Pathways and Drug Targets
              • Pathogenesis and Drug Targets
          • Epidemiology
            • Key Findings
              • Epidemiology Populations
                • Disease Definition
                • Methods
                • Sources Used for Total Prevalence of Psoriatic Arthritis
                • Number of Total Prevalent Cases of Psoriatic Arthritis in the Major Pharmaceutical Markets: 2019-2029 (thousands)
                • Sources Used for Diagnosed Prevalence of Psoriatic Arthritis
                • Diagnosed Prevalent Cases of Psoriatic Arthritis: 2019-2029 (thousands)
                • Sources Used for Diagnosed Drug-Treated Prevalence of Psoriatic Arthritis
                • Diagnosed Drug-Treated Prevalent Cases of Psoriatic Arthritis: 2019-2029 (thousands)
            • Current Treatment
              • Key Findings
                • Treatment Goals
                  • Key Endpoints Used in Clinical Trials for PsA
                • Key Current Therapies
                  • Overview
                  • Mechanism of Action of Key Current Drug Classes Used for PsA
                  • Current Treatments Used for PsA
                  • Market Events Impacting the Use of Key Current Therapies in PsA
                  • Advantages and Disadvantages of TNF-α Inhibitors
                  • Expert Insight: TNF Inhibitors
                  • Advantages and Disadvantages of Ustekinumab
                  • Ongoing Clinical Development
                  • Expert Insight: Ustekinumab
                  • Advantages and Disadvantages of Secukinumab
                  • Ongoing Clinical Development
                  • Expert Insight: Secukinumab
                  • Advantages and Disadvantages of Brodalumab
                  • Expert Insight: Brodalumab
                  • Advantages and Disadvantages of Ixekizumab
                  • Ongoing Clinical Development Program of Ixekizumab
                  • Advantages and Disadvantages of Guselkumab
                  • Ongoing Clinical Development
                  • Expert Insight: Guselkumab
                  • Advantages and Disadvantages of Tofacitinib
                  • Expert Insight: Tofacitinib
                  • Advantages and Disadvantages of Apremilast
                  • Ongoing Clinical Development
                  • Expert Insight: Apremilast
                  • Advantages and Disadvantages of Abatacept
                  • Ongoing Clinical Development of Abatacept
                  • Expert Insight: Abatacept
                  • Advantages and Disadvantages of cDMARDs
                  • Expert Insight: cDMARDs
                • Medical Practice
                  • Overview
                  • Country-Specific PsA Treatment Guidelines
                  • Factors Influencing Drug Selection in PsA
                  • Treatment Decision Tree for PsA: United States
                  • Treatment Decision Tree for PsA: Europe
                  • Treatment Decision Tree for PsA: Japan
              • Unmet Need Overview
                • Current and Future Attainment of Unmet Needs in PsA
                • Top Unmet Needs in PsA: Current and Future Attainment
                • Expert Insight: Unmet Need in PsA
              • Emerging Therapies
                • Key Findings
                  • Key Emerging Therapies
                    • Key Emerging Therapies in Development for PsA
                    • Estimated Launch Dates of Key Emerging Therapies for the Treatment of PsA
                    • Bimekizumab Profile
                    • Key Ongoing Clinical Trials of Bimekizumab in the Treatment of PsA
                    • Analysis of the Clinical Development Program for Bimekizumab
                    • Expert Insight: Bimekizumab
                    • Expectations for Launch and Sales Opportunity of Bimekizumab in Psoriatic Arthritis
                    • Upadacitinib Profile
                    • Key Ongoing Clinical Trials of Upadacitinib in the Treatment of Psoriatic Arthritis
                    • Analysis of the Clinical Development Program for Upadacitinib
                    • Expert Insight: Upadacitinib
                    • Expectations for Launch and Sales Opportunity of Upadacitinib in PsA
                    • Filgotinib Profile
                    • Key Ongoing Clinical Trials of Filgotinib in the Treatment of PsA
                    • Analysis of the Clinical Development Program for Filgotinib
                    • Expert Insight: Filgotinib
                    • Expectations for Launch and Sales Opportunity of Filgotinib in PsA
                    • Risankizumab Profile
                    • Key Ongoing Clinical Trials of Risankizumab in the Treatment of PsA
                    • Analysis of the Clinical Development Program for Risankizumab
                    • Expert Insight: Risankizumab
                    • Expectations for Launch and Sales Opportunity of Risankizumab in PsA
                    • Tildrakizumab Profile
                    • Key Ongoing Clinical Trials of Tildrakizumab in the Treatment of PsA
                    • Analysis of the Clinical Development Program for Tildrakizumab
                    • Expert Insight: Tildrakizumab
                    • Expectations for Launch and Sales Opportunity of Tildrakizumab in PsA
                  • Early-Phase Pipeline Analysis
                    • Select Compounds in Early-Phase Development for PsA
                • Access and Reimbursement Overview
                  • Region-Specific Reimbursement Practices
                    • General Reimbursement Environment: United States
                    • General Reimbursement Environment: EU5
                    • General Reimbursement Environment: Japan
                • Appendix
                  • Key Abbreviations Related to PsA
                  • Brands, Marketers, and Generic Availability of Key Therapies for Psoriatic Arthritis by Market
                  • Bibliography

              Author(s): Michael Pereira, Ph.D.; T.J. Arndt, M.P.H., C.P.H.

              Michael J. Pereira, M.S., Ph.D., is a business insights analyst on the Immune and Inflammatory Diseases team at DRG, part of Clarivate. He earned his M.S. in microbiology from the University of Rhode Island and his Ph.D. from Tufts University Graduate School of Biomedical Sciences. Before joining DRG, Dr. Pereira conducted scientific research at Tufts University, where he studied complement resistance by Borrelia burgdorferi, the cause of Lyme disease.

              Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master's degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.

               


              Related Reports

              Psoriatic Arthritis | Disease Landscape and Forecast | G7 | 2020

              A series of launches are expected to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market over the next 10 years and challenge the dominance of the TNF inhibitors; the...

              View Details

              Psoriatic Arthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US) Dashboard

              Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (

              View Details

              Psoriatic Arthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US)

              Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (

              View Details